NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.1b

Last Updated

2021/04/18 22:24 UTC

Data Sources

Company Financials +

Executive Summary

Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Aclaris Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ACRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ACRS's weekly volatility has decreased from 33% to 10% over the past year.


Market Performance


7 Day Return

-7.9%

ACRS

2.3%

US Pharmaceuticals

1.3%

US Market


1 Year Return

2,123.3%

ACRS

8.9%

US Pharmaceuticals

53.9%

US Market

Return vs Industry: ACRS exceeded the US Pharmaceuticals industry which returned 8.9% over the past year.

Return vs Market: ACRS exceeded the US Market which returned 53.9% over the past year.


Shareholder returns

ACRSIndustryMarket
7 Day-7.9%2.3%1.3%
30 Day-0.4%2.1%5.3%
90 Day353.7%-0.6%8.9%
1 Year2,123.3%2,123.3%13.1%8.9%56.6%53.9%
3 Year50.5%50.5%38.5%26.5%64.4%53.6%
5 Year35.7%35.7%46.8%27.7%120.4%95.7%

Long-Term Price Volatility Vs. Market

How volatile is Aclaris Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aclaris Therapeutics undervalued compared to its fair value and its price relative to the market?

31.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ACRS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ACRS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ACRS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ACRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACRS is overvalued based on its PB Ratio (32x) compared to the US Pharmaceuticals industry average (3.8x).


Future Growth

How is Aclaris Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

4.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACRS's revenue (35.4% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: ACRS's revenue (35.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ACRS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Aclaris Therapeutics performed over the past 5 years?

-17.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACRS is currently unprofitable.

Growing Profit Margin: ACRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACRS is unprofitable, and losses have increased over the past 5 years at a rate of 17.3% per year.

Accelerating Growth: Unable to compare ACRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACRS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).


Return on Equity

High ROE: ACRS has a negative Return on Equity (-135.87%), as it is currently unprofitable.


Financial Health

How is Aclaris Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ACRS's short term assets ($57.5M) exceed its short term liabilities ($14.9M).

Long Term Liabilities: ACRS's short term assets ($57.5M) exceed its long term liabilities ($18.3M).


Debt to Equity History and Analysis

Debt Level: ACRS's debt to equity ratio (28.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ACRS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ACRS has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 24.9% each year.


Dividend

What is Aclaris Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

Neal Walker (50 yo)

8.75yrs

Tenure

US$3,150,021

Compensation

Dr. Neal S. Walker, D.O., Co-founded Aclaris Therapeutics, Inc. in 2012 and also has been its Chief Executive Officer and President since July 2012. Dr. Walker is also Co-Founding Member and Partner of NeX...


CEO Compensation Analysis

Compensation vs Market: Neal's total compensation ($USD3.15M) is above average for companies of similar size in the US market ($USD2.32M).

Compensation vs Earnings: Neal's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ACRS's management team is considered experienced (4.9 years average tenure).


Board Members

Experienced Board: ACRS's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.9%.


Top Shareholders

Company Information

Aclaris Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aclaris Therapeutics, Inc.
  • Ticker: ACRS
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.132b
  • Shares outstanding: 51.80m
  • Website: https://www.aclaristx.com

Number of Employees


Location

  • Aclaris Therapeutics, Inc.
  • 640 Lee Road
  • Suite 200
  • Wayne
  • Pennsylvania
  • 19087
  • United States

Listings


Biography

Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Th...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/18 22:24
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.